NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. SEE TECHNICAL COMMENTS IN THE CHARETS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
GRPN: Shares float is 382.90M
News: Groupon takeover rumors still circulating. Piper Jaffray analyst Samuel Kemp applauded the company’s cost-cutting initiatives and suggested that Groupon could be a takeover target. IAC CEO Joey Levin just joined Groupon’s board, and his company owns a collection of brands. “We believe there’s a reasonable probability that Groupon could be acquired by IAC, especially if the public markets do not better reflect the fair value of Groupon,” Kemp wrote.
AEMD: Shares float of 7.63 Million
News: Shareholder were not impressed with the news on September 14th that the National Cancer Institute (NCI) has awarded the Company a government contract which runs from September 15, 2017, through June 14, 2018. The total amount of the firm fixed price contract is $299,250. In my opinion, The substantial dip since Sept 14th was way overdone as shown by the strong price move on Thursday with a close very near the HOD. I expect we'll see more upward price movement on Friday. But make sure you have a tight stop in place as this may be a dead cat bounce.
ATOS: Shares float of 11.37 million with 6.19% short.
News - On Monday, (ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions announced that it has contracted with a leading European hospital to conduct a Phase 2 study of its proprietary topical Endoxifen for the treatment of women with mammographic breast density, or MBD. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer.
ATOS was also featured in the monthly newsletter of Vista Partners with a good article about ATOS and their believe that their innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place to increasing the odds of surviving for those who do develop this deadly disease.
MNKD: Shares float of 80.6 million.
News - MannKind Corp. (MNKD) shares have made a substantial move since early May after it was announced that its One Drop|Chrome is now available on Amazon Prime. Overall this is huge because the diabetes testing system is now being listed on perhaps the world’s largest online marketplace.
According to Zacks Research last week, options traders are pricing in a big move for MannKind shares.